Rare Disease Regulatory Pathways & Orphan Drug Economics: Innovation vs. Access
Description
Rare disease therapies dominating recent approvals. Orphan drug pricing pressure increasing. Fast Track, Breakthrough Therapy, Accelerated Approval pathways enabling innovation. Reimbursement model restructuring needed for small populations.
Table of Contents
68 Pages
- EXECUTIVE SUMMARY
- 1.1 Rare Disease Regulatory Landscape
- 1.2 Orphan Drug Market Dynamics
- 2.0 REGULATORY PATHWAYS
- 2.1 Fast Track Designation
- 2.2 Breakthrough Therapy
- 2.3 Accelerated Approval
- 3.0 PRICING & REIMBURSEMENT
- 3.1 Orphan Drug Pricing
- 3.2 Payer Thresholds
- 3.3 Patient Access Models
- 4.0 DEVELOPMENT ECONOMICS
- 4.1 Cost-Benefit Analysis
- 4.2 Funding Challenges
- 4.3 Partnership Strategies
- 5.0 STRATEGIC PLANNING
- 5.1 Target Selection
- 5.2 Regulatory Engagement
- 5.3 Access Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



